Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

Expert review of clinical pharmacology - 1 Jun 2026

Zhang Tianqiao, Xu Bo, Chen Jixiang, Zhou Jiecan

Abstract excerpt

INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disease characterized by hemolytic anemia, bone marrow failure, and thrombosis. Some PNH patients carrying the C5 mutation (Arg885) show poor response to eculizumab and ravulizumab. AREAS COVERED: The US FDA approved PiaSky (crovalimab-akkz) on 20 June 2024, for use in adults or adolescents with PNH. It is a humanized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement C5

Share to Hemoglobinuria, Paroxysmal

Share to Hemolysis

Share to Mutation

Source

Identifiers

PMID: 42215427
DOI: 10.1080/17512433.2026.2677883

Genes

C5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.PMID 42215427Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic StrategiesSemantic proximity Read ↗

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaSemantic proximity Read ↗

Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.Semantic proximity Read ↗

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.Semantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Biology and TreatmentSemantic proximity Read ↗

Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitorSemantic proximity Read ↗

[Paroxysmal nocturnal hemoglobinuria: from physiopathology to treatment].Semantic proximity Read ↗

Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.